Page last updated: 2024-10-22

ambroxol and Dementia

ambroxol has been researched along with Dementia in 1 studies

Ambroxol: A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride.

Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.

Research Excerpts

ExcerptRelevanceReference
"Ambroxol is a pharmacological chaperone for GCase and is able to raise the levels of GCase and could therefore be a disease-modifying treatment for PDD."6.90Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial. ( Bartha, R; Borrie, M; Coleman, K; Finger, E; Hegele, RA; Jenkins, ME; Jog, M; Li, Z; MacDonald, P; MacKinley, J; Mahuran, D; Morrow, SA; Pasternak, SH; Rupar, CA; Silveira, CRA; Tirona, RG; Wells, J; Zou, G, 2019)
"Ambroxol is a pharmacological chaperone for GCase and is able to raise the levels of GCase and could therefore be a disease-modifying treatment for PDD."2.90Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial. ( Bartha, R; Borrie, M; Coleman, K; Finger, E; Hegele, RA; Jenkins, ME; Jog, M; Li, Z; MacDonald, P; MacKinley, J; Mahuran, D; Morrow, SA; Pasternak, SH; Rupar, CA; Silveira, CRA; Tirona, RG; Wells, J; Zou, G, 2019)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Silveira, CRA1
MacKinley, J1
Coleman, K1
Li, Z1
Finger, E1
Bartha, R1
Morrow, SA1
Wells, J1
Borrie, M1
Tirona, RG1
Rupar, CA1
Zou, G1
Hegele, RA1
Mahuran, D1
MacDonald, P1
Jenkins, ME1
Jog, M1
Pasternak, SH1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Ambroxol as a Novel Disease Modifying Treatment for Parkinson's Disease Dementia[NCT02914366]Phase 255 participants (Actual)Interventional2015-11-30Active, not recruiting
Ambroxol as a Disease-modifying Treatment to Reduce the Risk of Cognitive Impairment in GBA-associated Parkinson's Disease. A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Trial[NCT05287503]Phase 265 participants (Actual)Interventional2022-02-15Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for ambroxol and Dementia

ArticleYear
Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.
    BMC neurology, 2019, Feb-09, Volume: 19, Issue:1

    Topics: Aged; Ambroxol; Brain; Dementia; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson D

2019
Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.
    BMC neurology, 2019, Feb-09, Volume: 19, Issue:1

    Topics: Aged; Ambroxol; Brain; Dementia; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson D

2019
Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.
    BMC neurology, 2019, Feb-09, Volume: 19, Issue:1

    Topics: Aged; Ambroxol; Brain; Dementia; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson D

2019
Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.
    BMC neurology, 2019, Feb-09, Volume: 19, Issue:1

    Topics: Aged; Ambroxol; Brain; Dementia; Double-Blind Method; Female; Humans; Male; Middle Aged; Parkinson D

2019